News
FDA fast-tracks CER-1236, a novel immunotherapy for acute myeloid leukemia, enhancing its development and potential market ...
Intellia’s CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T ...
TipRanks on MSN6d
CERo Therapeutics Gains Fast Track for AML Drug
CERo Therapeutics Holdings ( (CERO) ) has issued an update. On September 5, 2025, CERo Therapeutics Holdings announced that its lead investigational compound, CER-1236, received Fast Track ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback